SLC2A3 and cancer: Transactivation of GLUT3 occurs in a Yes-associated protein (YAP)-dependent manner, suggesting that this pathway serves as a regulator of metabolic reprogramming during cancer progression, and thus can be considered as a promising anti-cancer therapeutic target [76].